Healthtech Memed Accelerates Growth With New US$14 Million Investment

Memed, the Brazilian electronic prescription healthtech, has secured a US$ 14 million funding round to accelerate the development of artificial intelligence solutions for healthcare and expand its digital infrastructure across the country.

The round was co-led by DGF and BridgeOne, with participation from DNA Capital. According to the company, the new capital will primarily support investments in engineering, product development, and data science, as well as the hiring of new technology and product professionals.

Memed Plans to Go Beyond Digital Prescriptions

Since reaching profitability in June 2025, Memed has shifted its focus toward scaling its operations and strengthening its position as a broader healthcare infrastructure platform.

Rodolfo Chung, CEO of Memed and former CEO of Zé Delivery, stated that the company’s strategy is no longer centered solely on the transition from paper prescriptions to digital prescriptions.

“The discussion is no longer about whether prescriptions will migrate to digital. The question now is how to transform this migration into real productivity gains and clinical quality improvements for physicians,” Chung said in a statement.

The company now aims to expand its role in treatment monitoring and healthcare workflows by integrating artificial intelligence directly into the clinical process.

Artificial Intelligence Becomes Central to the Prescription Process

Fabio Tabalipa, medical director at Memed, explained that AI is not being added merely as an extra software layer but as a core component of medical prescribing.

According to him, physicians receive real-time clinical context during the prescription process, including medication interaction alerts, dosage recommendations adapted to patient profiles, and additional clinical warnings that previously required consulting multiple sources.

“This is not an interface improvement. It is a structural change in the way clinical practice happens, with direct impact on patient safety and physician productivity,” said Tabalipa.

Over the next 24 months, Memed plans to launch additional AI-powered prescription tools, deepen integrations with electronic medical records and hospital systems, and expand its structured clinical data capabilities.

Profitability Changed the Company’s Growth Strategy

Memed reached breakeven after years of cash burn, a milestone the company attributes in part to the strategic repositioning led by Chung.

The CEO identified that the company’s strongest opportunity was helping pharmaceutical companies improve communication with physicians through its platform. Following the operational turnaround, Memed now projects revenue of US$17.5 million by the end of 2026.

Earlier this year, Chung stated in an interview that the company’s long-term ambition is to become a unicorn within four to five years, potentially preparing for an IPO in the future.

Investors Highlight Memed’s Data and Network Effects

Investors participating in the round emphasized Memed’s position within Brazil’s healthcare ecosystem and the strategic value of its data infrastructure.

Frederico Greve, partner at DGF, noted that Memed has spent more than a decade building network effects that connect physicians, pharmacies, and the pharmaceutical industry.

“DGF has spent more than two decades investing in Brazilian B2B platforms that become infrastructure within their sectors — and the pattern we recognize in Memed is exactly that,” Greve stated.

Vinicius Portas, partner at BridgeOne, highlighted that the company’s competitive advantage extends beyond the size of its user base.

According to him, Memed has built a valuable repository of structured clinical practice data generated through genuine physician engagement, creating increasing value for healthcare operators and both public and private healthcare systems.

Meanwhile, Luiz Noronha, partner at DNA Capital, pointed to Memed’s market leadership, financial discipline, and agnostic business model serving physicians, patients, pharmacies, and the pharmaceutical industry simultaneously without conflicts of interest.